Baxalta submits application for immunoglobulin subcutaneous treatment
Baxalta Inc. announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of an investigational 20 percent concentration immunoglobulin subcutaneous treatment. Read More »